

The health revolution begins here...

FrissOn Capital has access to more than 500 startups in a sector that is being disrupted with no specialized investors or support systems

Join us to invest in the future of healthcare and bring ground-breaking innovations to the world

Introduction

FrissOn Capital proudly presents the **Exponential Health Fund (x^HF)**, a \$20 million pre-seed and seed venture capital fund targeting 40+ startups, projected to generate a 30-40% IRR while addressing global health challenges and driving the next wave of health innovation. The fund is strategically positioned in the U.S., Canada, and Latin America to empower early-stage health tech startups with capital and mentorship, which often struggle to secure the necessary capital and support to scale their groundbreaking solutions.

x^HF not only provides financial backing but also offers access to a comprehensive support ecosystem, starting from access to a comprehensive support ecosystem, including partnerships with business readiness accelerators in Chile and Technology Readiness Programs in Academic institutions in Canada, including industry mentorship, strategic partnerships, and global market opportunities.

x^HF aims to empower entrepreneurs who are developing frontier technologies capable of addressing global health issues head-on. FrissOn Capital's focus spans cutting-edge innovations such as Al-driven diagnostics, biotechnology, telemedicine platforms, and advanced medical devices. By investing in the most promising startups, x^HF is poised to transform the health landscape globally, creating scalable solutions with massive reach. With deep expertise in both venture capital and health sectors, FrissOn Capital brings a track record of scaling impactful startups.

FrissOn Capital has built a robust network of stakeholders, including research institutions, healthcare providers, and international investors, to ensure its portfolio companies have the resources to thrive.

x^HF is more than an investment vehicle—it is a catalyst for change, accelerating the development of technologies that will revolutionize healthcare systems and improve quality of life across the Americas.



The Need / Significance

The health sector is undergoing a significant transformation, driven by a growing ecosystem of innovative startups that are leveraging cutting-edge technologies—such as artificial intelligence (AI), biotechnology, and advanced medical devices—to tackle pressing healthcare challenges.

Despite this surge of innovation, there remains a critical funding gap at the pre-seed and seed stages, which hampers the ability of early-stage companies to secure the resources necessary for development, market validation, and scaling. This lack of capital presents a major obstacle for entrepreneurs in the health sector who are creating solutions capable of transforming delivery and outcomes.

While health tech investments have grown exponentially—with total funding raised per year in Latin America by health techs increasing 4,700% from 2015 to 2021, for example—the majority of this capital is concentrated in later stages of funding. Early-stage ventures, particularly those in the pre-seed phase, often find themselves without access to the financial support they need to move forward.

According to data from FrissOn Capital's ecosystem monitoring efforts, over 500 health tech startups and 250 support organizations face funding shortages, delaying innovations that could reduce healthcare costs by 20% or improve diagnostics by 30%.

This funding gap not only stifles innovation but also delays the development of critical solutions that could improve access to care, reduce costs, and address the region's most pressing public health issues.

The Need / Significance

Latin America in particular continues to grapple with profound healthcare disparities. These systemic challenges create fertile ground for ingenuity for health tech solutions, particularly those that can offer scalable, technology-enabled services such as biotech, Al-powered diagnostics, and mobile health platforms.

The Exponential Health Fund (x^HF) is designed to address this unmet need by providing targeted investment at the pre-seed stage, coupled with strategic mentorship, industry connections, and operational support

By focusing on early-stage ventures that are poised to deliver measurable impact in healthcare, x^HF not only fills a critical funding gap but also plays a pivotal role in driving the region's broader health tech revolution.

FrissOn Capital's fund aims to support startups that can develop sustainable global business models and innovative technologies, ensuring that they reach both global markets. This strategy will accelerate the growth of a new generation of health tech leaders who have the potential to revolutionize healthcare systems, ultimately improving patient outcomes and reducing healthcare costs. Unlike traditional funds, x^{HF} provides non-dilutive funding and cross-border support, multiplying investments by 5-10x.

Objectives

The Exponential Health Fund (x^HF) is strategically designed to achieve a set of ambitious but attainable objectives that will drive both financial returns and transformative impact in the health tech sector.


The following objectives outline the fund's investment focus, target outcomes, and key performance indicators (KPIs) that will guide its deployment:

Fund Objective

The primary goal of x^{HF} is to raise and deploy \$20 million in capital, dedicated to investing in over **40** pre-seed and seed stages health tech startups.

By injecting capital into these early-stage ventures, xHF aims to bridge the critical funding gap that hampers the growth of health tech innovation in the region.

The fund's deployment will be carefully timed and managed over the course of a 10-year lifecycle to ensure optimal growth and maturation of portfolio companies, allowing them to secure follow-on investments and scale both regionally and globally.



Investment Focus

x^HF will concentrate on frontier tech startups that are leveraging transformative technologies such as artificial intelligence (AI), biotechnology, and medical devices.

These startups have the potential to address some of the most pressing healthcare challenges, including access to care, diagnostic inefficiencies, and high treatment costs.

Each initial investment will range from \$150K to \$200K per startup, plus a \$350K to \$500K follow on for startups that demonstrate strong progress (typically 40% of FrissOn Capital's portfolio) to provide the necessary capital for these companies to reach critical development milestones by achieving maturity at the technology readiness level (TRL), business readiness level (BRL) and investment readiness level (IRL).

By focusing on high-potential health tech sectors, x^HF ensures that its portfolio is positioned at the cutting edge of healthcare innovation, setting the stage for significant regional and global impact.



Objectives

Impact Goal

Beyond financial returns, xHF is committed to driving measurable improvements in healthcare access, outcomes, and efficiency. The fund aims to accelerate the development and adoption of health solutions that can directly impact the quality of care delivered to millions of patients.

This includes fostering innovations that lower healthcare costs, enhance diagnostic accuracy, and improve patient outcomes, particularly in underserved and marginalized populations.

By empowering a new generation of health tech startups, x^HF will contribute to strengthening the healthcare systems and boosting the global competitiveness in the health sector.

Global Expansion

In addition to fostering regional growth, xHF is dedicated to enabling startups to scale globally, particularly the U.S. and Canadian markets.

By providing strategic guidance and leveraging an extensive network of partners and investors in the U.S. and Canada, x^HF will facilitate access to global markets for its portfolio companies

This expansion in the U.S. and Canada will provide these startups with the opportunity to scale their solutions on a larger platform, gain international exposure, and drive global adoption of their innovations, positioning them as key players in the international health landscape.

Key Performance Indicators (KPIs)

Internal Rate of Return (IRR)

x^HF is targeting an IRR of 30-40% over its 10-year fund lifecycle, demonstrating that impactful investments in health tech startups can yield strong financial returns while driving positive social and economic outcomes.

Achieving this IRR will require a diversified portfolio that balances risk across different technologies and markets.

Portfolio Diversification

The fund will prioritize creating a diversified portfolio of startups addressing a range of critical health challenges, from chronic disease management and telemedicine to personalized medicine and digital health solutions.

They will be divided into 3 groups: deep tech, tech enabled, and tech based. This diversification strategy will reduce risk and increase the likelihood of backing startups that can achieve significant market penetration.

Startup Milestones

x^HF will actively support portfolio companies in achieving key development milestones, such as advancing their technology readiness levels (TRL), business readiness levels (BRL), and investment readiness levels (IRL).

These milestones are essential for ensuring that startups can successfully commercialize their innovations and attract follow-on investments from larger institutional investors.

Capital Crowded In

One of the key performance indicators for xHF will be the amount of capital invested in portfolio startups in subsequent funding rounds after FrissOn Capital's initial investment. This metric will track how effectively FrissOn Capital's support helps startups attract followon investments from other venture capital firms, corporate investors, and strategic partners.

By focusing on capital crowded in, x^HF will measure its ability to catalyze additional funding, ensuring that the startups in FrissOn Capital's portfolio have the financial backing necessary to scale and succeed in global markets.

Through these well-defined objectives and Key Performance Indicators (KPIs), x^HF is positioned to deliver both financial success and lasting societal impact, helping to shape the future of healthcare

FrissOn Capital Mode

Supporting Cross-Border Innovation from Prototype to Market

EARLY STAGE ENTREPRENEURS CAPABLE OF MASSIVE IMPACT

 Investing in Global South functioning prototypes automatically multiplies the investment 5x-10x.

2

MATURING AND DERISKING THE STARTUP

- Investment and Business Readiness with AceleraLatam.
- Technology Readiness with Be Ventures.

3

STRATEGY AND FUNDING

- Strong strategy: Corporate, IP, investment, finance, marketing, talent, and commercial.
- Non-Dilutive Capital: Tech maturity preserving equity and IP.

4

ARBITRAGE

- Investing in Global South functioning prototypes multiplies the investment **5x-10x**.
- Basing scaling in Global North (corporate and IP strategy) multiplies the investment
 3x.
- Taking advantage of nearshoring for R&D and manufacturing multiplies the investment **again**.

5

EXIT STRATEGY

- Funding: Help companies reach enough scale and maturity to raise their next round.
- Exit: Plan to exit via secondary exits at stages B or C, prioritizing liquidity and returning capital to LPs.

[&]quot;Global South" = Latin America, "Global North" = U.S. and Canada, "LatAm" = Latin America

FrissOn Capital is spearheaded by a dynamic, multidisciplinary team of accomplished entrepreneurs, seasoned investors, and industry veterans, each bringing deep expertise across health tech, venture capital, and frontier technologies.

With decades of collective experience in building and scaling companies, the team combines strategic vision with hands-on operational know-how to empower startups and drive transformative impact in the health innovation ecosystem.



Pedro Lopez Sela

MANAGING PARTNER

Argumenting Leaders to Thrive

A serial entrepreneur, venture builder, and investor with over 25 years of experience. Pedro has built and scaled tech companies globally, including leading the development of ecosystems in partnership with institutions like the US NSF, UK RAE, and WIPO.



lan Morales

VENTURES MANAGER

An entrepreneur with extensive experience in tech and venture building across Latin America and Asia. Ian has played key roles in developing innovation ecosystems.



Juana Ramírez

OUTREACH ADVISOR

Building the Foundation for Entrepreneurs

A health entrepreneur with a proven track record of building and scaling health-focused ventures. Juana is recognized for her commitment to giving back and supporting other entrepreneurs, and current President of the Entrepreneurs Association of Mexico.



Sebastián Molina Gasman

OPERATING ADVISOR

Connecting capital to changemakers

Early-stage venture capital investor with track record in emerging markets, with a particular emphasis in Latin America. Sebastián brings extensive experience in fund management and investment due diligence, offering valuable guidance to startups on strategic growth and securing follow-on funding.



Fernando Castilleja

ECOSYSTEM ADVISOR

Empowering Health Leaders

An MD and health ecosystem pioneer, Fernando has a deep understanding of health innovation and has been instrumental in fostering a collaborative environment for health startups.



Dorn Carranza

SCIENTIFIC ADVISOR

Boosting innovation in Latin America

A scientist-turned-entrepreneurial leader who brings expertise in biotechnology and scientific innovation, Dorn plays a key role in evaluating and guiding the technological aspects of portfolio companies.



Greg Bowman

VENTURE PARTNER

Advancing sustainability in deeveloping countries

Ex-Chairperson to Intergovernmental Organizations at the UN's Economic Social Division, Greg provides strategic insights into global health trends and connects startups to international networks.



Eugenio Cantuarias

VENTURE PARTNER

Accelerating Impact Development through startups

An engineer with over 15 years of experience in consulting and a passion for technology. He founded AceleraLatam and AceleraVentures, focusing on supporting early-stage startups. In 2021, he raised a \$5 million fund to invest in climate change solutions with ethical investment codes.



Javier Placer

VENTURE PARTNER

Disrupting disruptors to improve the world

Over 30 years of experience as a Special Situations Analyst, previously serving as CEO of Telefónica Open Future. He specializes in applying Machine Learning to business decisions and leads his own asset management and M&A companies, helping firms grow globally.



Roberto Alvarez

VENTURE PARTNER

Re-frame thinking to transform business, the economy & society

Over 25 years of experience in technology, business, and policy, with a portfolio of over 20 early-stage deals. He is a Venture Partner at Seldor Capital and founder of AVentures, specializing in space-tech and Industry 4.0. He also advises Bossa Nova Investments and has co-founded three tech companies.



Sitaramaraju Yarramraju

ADVISOR

With over 20 years in the pharmaceutical industry, Sitaramaraju is the founder and CEO of two companies transforming clinical research in Latin America. At Avant Santé, he provides high-quality research services to biopharmaceutical clients, while at EtCurae, he focuses on patient-centered research in public health. With a strong background in drug discovery, he is passionate about advancing clinical research and seeks collaborations to expand his impact globally.



Roberto Salinas León

ADVISOR

Liberating markets

An expert on economic policy and international trade with over 30 years of experience. He is President of the Alamos Alliance, Director of the Atlas Network's Center for Latin America, and has written over 2,000 editorials in top-tier publications on global economic issues.



Adriana Tortajada

ADVISOR

Pioneering in early-stage funding for future generations

A venture capital pioneer, key in creating the Latin America Impact Fund of Funds. With 20+ years in the financial sector, she designed Mexico's Venture Capital Fund of Funds and has a strong background in public fundraising and portfolio management.



Víctor Barajas

ADVISOR

Foreseeing a brighter future one estate at a time

A tax lawyer with extensive expertise in tax planning for multinational companies. He has held leadership roles in top tax organizations, including STEP Mexico, and focuses on corporate tax advisory and investment structuring for high-net-worth families and businesses.



Eugenio Marin

ADVISOR

Building Knowledge Economy

A mechanical engineer with over 18 years of experience scaling technology SMEs. He co-founded a startup in 2004 and has supported over 800 Mexican SMEs in international expansion. He currently serves as executive director at FUMEC, specializing in ICT and advanced manufacturing.



Plan of Work

FrissOn Capital adopts a structured, hands-on approach to investing and nurturing health tech startups across the U.S., Canada, and Latin America, employing a rigorous methodology from screening to exit (see the "FrissOn Capital Model" on page 6 above and "Our Model" on page 11 below).

Screening & Evaluation

FrissOn Capital conducts an exhaustive scouting process. It is projecting a 1% investment rate.

To date, FrissOn Capital has evaluated approximately 1,000 startups creating a robust pipeline for investment.

Its selection criteria emphasize technological innovation, team expertise, and alignment with FrissOn Capital's health and wellness mission.

The process also involves deep-dive evaluations of market size, business model sustainability, and growth potential, ensuring that selected startups meet FrissOn's stringent investment benchmarks.

Due Diligence

FrissOn Capital's due diligence process is comprehensive, assessing key factors such as technology readiness, team qualifications, regulatory hurdles, and intellectual property (IP) strategy.

This phase ensures that the startups FrissOn Capital backs are positioned to advance through critical development stages.

Special focus is placed on identifying projects with a clear trajectory towards achieving maturity at the Technology Readiness Level (TRL), Business Readiness Level (BRL), and Investment Readiness Level (IRL).

Investment

FrissOn Capital provides \$150K-\$200K in initial pre-seed funding to each selected startup, with follow-on investments of up to \$350K-\$500K available for those that demonstrate strong progress (which represent 40% of FrissOn Capital's portfolio).

The xHF fund targets a portfolio of **40+** startups, creating a diversified set of companies working across AI, biotechnology, medical devices, and other frontier health tech fields.



SCREENING EVALUATIONS


We meticulously scout top-tier deep tech projects aligning with our investment criteria, ensuring each has a functional prototype.

EVALUATIONS

Our Investment
Committee conducts
initial evaluations,
handpicking projects
with promising
potential to move
forward into full due
diligence.

DUE DILIGENCE EXPERTS

Selected projects undergo comprehensive due diligence, rigorously assessing technology feasibility, team expertise, and sustainable business models.





EXPERTS

Our expert board conducts in-depth technology reviews, offering invaluable guidance and becoming integral members of the startup's advisory board.

ACCELERATION TECH DEV

Projects progress either to Canada for technology development towards TRL 9 and/or to Chile to achieve BRL and IRL 9 milestones, tailored to their specific needs.

ACCELERATION

We support and crystalize the corporate and IP strategies defined during the IRL-BRL acceleration and TRL scaling.

EXIT

We provide comprehensive support to each project, guiding them through to **Series A**, nurturing their growth and success every step of the way.

<u>Acceleration & Incubation Programs</u>

Startups benefit from FrissOn Capital's robust acceleration and incubation platforms, including participation in the Evidence Based Entrepreneurship & Lean Innovation (EBELI) program, a health innovation incubator that combines lean startup methodologies with experimental learning.

Theseprogramsprovide tailored mentorship, accesstostrategicpartnerships, and resources to help startups refine their business models, navigate regulatory environments, and scale operations.

Additionally, startups are connected to FrissOn Capital's international network, with key partnerships in Canada and Chile, offering support for technology transfer, IP protection, and market entry strategies.

Strategic Support

Beyond funding, FrissOn Capital offers comprehensive support, including technical assistance, corporate strategy guidance, regulatory navigation, and assistance with commercial scaling.

Startups also gain access to FrissOn Capital's **Health Entrepreneurship Mentors Network**, a specialized network of health tech experts that supports the maturation of innovations from proof of concept to market deployment.

Exit Strategy

FrissOn Capital's exit strategy targets secondary sales to other venture capital investors during Series A or B fundraises, prioritizing liquidity in its investments.

Opportunistically, FrissOn Capital may opt for partial exits at those stages in order to retain additional upside.

FrissOn Capital focuses on companies with strong market positioning and growth potential.

These exits aim to deliver substantial returns to FrissOn's limited partners (LPs), while ensuring that startups remain aligned with their mission to drive health innovation.

By leveraging its incubation and acceleration programs, combined with a network of experts and strategic partnerships, FrissOn Capital aims to cultivate and scale groundbreaking health technologies across the Americas

Timeline

FrissOn Capital's timeline encompasses the strategic phases of the Exponential Health Fund (x^{HF}) to ensure effective deployment and management of investments. Key milestones and activities are:

Q1 2025

Finalize the fundraising phase and officially launch the fund. This phase includes securing commitments from limited partners (LPs), establishing fund operations, and onboarding the management team.

By the end of this quarter, FrissOn Capital will initiate outreach to potential startups and begin preparing for the first investment round.

Q2-Q4 2025

Execute the initial screening and evaluation process to identify high-potential startups for the first investment cohort.

During this period, FrissOn Capital aims to invest in 10-12 startups, providing them with initial funding and integrating them into its acceleration programs.

This phase will also involve setting up the operational framework for ongoing support and monitoring.

2025-2028

Expand the investment activity to include additional startups, with the goal of building a diversified portfolio of up to 40 companies. This period will see continued scouting, due diligence, and funding of startups, with a focus on scaling investments and providing strategic support.

FrissOn Capital's acceleration programs will be instrumental in guiding these startups through critical growth stages.

2026-2029

Start and then concentrate on follow-on investments to support the growth and scaling of portfolio companies.

This phase involves monitoring performance, assessing needs for additional funding, and preparing companies for exit opportunities. FrissOn Capital will work closely with portfolio companies to optimize their strategies and enhance their market positions.

2032-2034

Prioritize exits through secondary sales and mergers and acquisitions (M&As).

The goal during this period is to achieve liquidity events that return capital to FrissOn Capital's LPs while ensuring that portfolio companies transition smoothly and continue their growth trajectories.

This phase will involve strategic exit planning, engagement with potential acquirers or investors, and execution of exit transactions.

Additional Detail: The timeline is subject to adjustments based on market conditions, startup performance, and evolving industry trends.

Flexibility will be maintained to adapt to unforeseen developments and ensure alignment with the fund's objectives and the evolving needs of the portfolio companies.

Expected/Desired Outcomes

FrissOn Capital's Exponential Health Fund (xHF) is designed to drive transformative changes in the health tech sector.

The expected outcomes reflect FrissOn Capital's commitment to creating a substantial impact through strategic investments and comprehensive support. The key outcomes are:

Portfolio Maturity

FrissOn Capital aims to build a diversified portfolio of over 40 high-impact startups. These startups will be at the forefront of health technology, advancing innovations in areas such as AI, biotechnology, and medical devices.

FrissOn Capital's target is to achieve an internal rate of return (IRR) of 30-40% over the fund's lifecycle, demonstrating strong financial performance and value creation for its limited partners (LPs). A \$200K investment could yield \$1.2M over 10 years at a 35% IRR under the base-case scenario.

Market Impact

The x^HF seeks to catalyze significant growth in the health tech startup sector within the Americas with a focus on entrepreneurs in Latin America.

This will be measured by enhancements in healthcare accessibility, such as improved service delivery in underserved regions, and better patient outcomes through the adoption of innovative health solutions.

FrissOn Capital' investments are expected to contribute to a more competitive global market presence for Latin American health tech startups, elevating their visibility and influence on the international stage.

Ecosystem Development

A core objective of the xHF is to strengthen the regional health innovation ecosystem. By supporting early-stage ventures, FrissOn Capital aims to develop a robust pipeline of health tech startups capable of addressing critical health challenges.

This includes fostering collaborations among startups, industry stakeholders, and academic institutions to create a sustainable and dynamic ecosystem that drives ongoing innovation and growth.

Metrics for Success

Job Creation

Track the number of new jobs created by portfolio companies, reflecting the fund's contribution to economic growth and workforce development within the region.

Healthcare Improvements

Assess improvements in healthcare delivery, such as reduced costs, increased access to care, and enhanced patient outcomes facilitated by the technologies and solutions developed by funded startups.

Technological Advancements

Measure advancements and innovations achieved by portfolio companies, including successful technology deployments, patents filed, and milestones reached in technology readiness levels (TRL), business readiness levels (BRL), and investment readiness levels (IRL).

Through these outcomes, FrissOn Capital aims to make a lasting impact on the health tech landscape, fostering a thriving ecosystem that not only addresses pressing health challenges but also generates significant economic and social value.

Methods of Evaluation

To ensure the effectiveness of the Exponential Health Fund (xHF) and its alignment with FrissOn Capital's objectives, FrissOn will implement a comprehensive evaluation strategy. This strategy will focus on performance metrics, impact assessment, and ongoing reviews to monitor progress and make necessary adjustments.

Performance Metrics

FrissOn Capital will closely monitor several key financial and operational indicators:

Internal Rate of Return (IRR) and Multiple on Invested Capital (MOIC): These financial metrics will be tracked to assess the overall profitability and return on investment of the fund.

Startup Growth Metrics: The growth of portfolio companies will be evaluated through revenue generation, user adoption rates, and market penetration. These metrics will help gauge the success and scalability of the startups in which FrissOn Capital invests.

Exit Outcomes: Exit strategies and outcomes will be analyzed, including secondary sales, mergers, and acquisitions, to determine the realization of returns and the fund's overall financial performance.

Impact Assessment

Measuring the social and economic impact of FrissOn Capital's investments is crucial:

Exit Outcomes: Exit strategies and outcomes will be analyzed, including secondary sales, mergers, and acquisitions, to determine the realization of returns and the fund's overall financial performance.

Healthcare Access: Improvements will be assessed in access to healthcare services resulting from FrissOn Capital's portfolio companies' innovations, such as expanded

reach to underserved populations.

Quality of Care: Enhancements in the quality of healthcare services and patient outcomes will be evaluated, including reductions in treatment costs and improvements in care efficiency.

Innovation: The advancement of new technologies and solutions introduced by startups will be tracked, including their adoption in the market and their contributions to addressing key health challenges.

Annual Reviews

To maintain a rigorous evaluation process:

Portfolio Health: Annual reviews will be conducted to evaluate the overall health of the portfolio, including the performance and progress of each startup.

Investment Strategy Effectiveness: The effectiveness will be reviewed of FrissOn Capital's investment strategies, including deal flow quality, due diligence processes, and support mechanisms provided to startups.

Impact Metrics: Reassess impact metrics to ensure alignment with FrissOn Capital's goals and to identify areas for improvement.



Methods of Evaluation

Continuous Feedback

Implement a continuous feedback loop to refine FrissOn Capital's strategies based on performance and impact data.

This iterative approach will involve regular adjustments to FrissOn Capital's investment and support strategies to optimize outcomes and respond to emerging trends and challenges.

Framework

Utilize established impact evaluation frameworks and benchmarks to systematically assess progress toward healthcare and social objectives. This will include:

Benchmarking: Compare FrissOn Capitals performance against industry standards and best practices to ensure FrissOn Capital are meeting or exceeding expectations.

Impact Frameworks: Apply recognized frameworks for evaluating social impact to measure progress in areas such as health improvement, economic development, and technological advancement.

Through these evaluation methods, FrissOn Capital will ensure that the x^HF not only achieves its financial goals but also delivers significant positive impacts on the healthcare sector

Funding Request

The budget for the Exponential Health Fund (xHF) has been meticulously planned to ensure optimal deployment of resources and effective management of the fund. Here is a detailed breakdown of the financial requirements and allocations:

Total Fund Size

FrissOn Capital is seeking to raise a total of \$20 million.

This capital will be strategically invested to support early-stage health tech startups and drive significant advancements in the health sector.

Management Fee

A management fee of 2% per annum will be applied to cover fund operations, due diligence, acceleration programs, and ongoing portfolio management.

This fee ensures the fund can maintain high standards in its operations and support its investments effectively.

Carried Interest

FrissOn Capital proposes a 20% carried interest, which serves as a performance-based incentive for achieving targeted financial returns.

This structure aligns the interests of the fund managers with those of the investors, ensuring that the focus remains on maximizing returns and driving successful outcomes.

Investment Allocation

Pre-Seed Investments: Allocate approximately \$150K-\$200K to each of 40 startups at the pre-seed stage. This initial capital will enable startups to develop their technologies and achieve early milestones.

Follow-On Investments: Reserve up to \$350K-\$500K for follow-on investments in 16 companies that demonstrate significant potential and need additional funding to scale and reach later-stage milestones.

Funding Request

Operating Budget Breakdown

The operating budget will be allocated as follows:

Personnel and Salaries: Cover compensation for the fund's management team, including roles in investment analysis, portfolio management, and support services.

Due Diligence and Legal Expenses: Fund costs associated with thorough due diligence processes and legal services necessary for investment transactions and compliance.

Acceleration Program Costs: Include expenses for running acceleration programs, such as travel for mentors and partners, partnership costs, and resources needed to support startup growth.

Marketing and Deal Sourcing: Invest in marketing efforts and deal with sourcing activities to identify and attract high-quality investment opportunities. This includes outreach, networking events, and promotional activities.

Administrative and Operational Expenses: Cover general administrative costs, including office space, utilities, technology infrastructure, and other operational needs to ensure the smooth functioning of the fund.

This detailed budget ensures that the xHF is well-equipped to achieve its investment goals, support portfolio companies effectively, and manage operations efficiently.

FrissOn Capital believes that this financial plan will deliver substantial returns to its investors while driving meaningful advancements in health tech.



Long-Term Plans

The Exponential Health Fund (xHF) aims to establish itself as the leading venture capital fund for health tech in Latin America. Over the next decade, FrissOn Capital plans to:

Scale Impact

As FrissOn Capital achieves success with the xHF fund, it plans to launch subsequent funds focused on supporting startups through the early-stage lifecycle, with a focus on Seed and Series A. Additionally, FrissOn Capital will expand its geographic focus to include other emerging markets in the global south.

This growth will allow us to increase invested capital and provide ongoing support to startups that have demonstrated significant potential, ensuring they can scale and compete globally.

Build a Legacy

FrissOn Capital's goal is to create a sustainable and dynamic venture capital ecosystem for health innovation from Latin America.

We aim to foster a culture of entrepreneurship and technological advancement by establishing robust support networks, training programs, and collaborations with universities and incubators. We want to act as a catalyst for the growth of the health tech industry, encouraging new entrepreneurs and creating opportunities that drive technological progress in the region.

Global Integration

FrissOn Capital will work to position portfolio companies for successful entry into global markets.

We will facilitate access to international networks, strategic partnerships, and collaboration opportunities with global health organizations.

By doing so, FrissOn Capital aims to establish Latin America as a prominent hub for health tech innovation, contributing to solving global health challenges and attracting international investments and talent to the region.





Long-Term Plans

Additional Strategies

Global Partnerships

FrissOn Capital will explore partnerships with international health and development organizations to strengthen its network and open new opportunities for portfolio startups. These collaborations may include coinvestment agreements, strategic alliances, and joint projects that enhance innovation and impact on health.

Scaling Acceleration Programs

FrissOn Capital will expand its acceleration programs to include a larger number of startups and offer specialized support in key areas such as global market access, technology development, and commercialization.

This expansion will help maximize the potential of emerging companies and ensure they are well-prepared to tackle global market challenges.

These long-term strategies ensure that xHF can achieve its immediate goals and establish a solid foundation for ongoing growth and lasting influence in the health and technology ecosystem

Join FrissOn Capital in shaping the future of healthcare through the Exponential Health Fund. Bepartofa pioneering initiativedelivering a 30-40% IRR while revolutionizing global health innovation. Contact us today to secure your investment and drive transformative impact in the health tech ecosystem.

Please respond to:

